LEADER®

CompletedPhase 3Results posted

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

428

Recruiting sites

—

Enrollment

9,341

actual

Study population

Cardiovascular disease, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•3-point MACE (Cardiovascular death, Non-fatal MI, Non-fatal stroke)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01179048

Org study IDEX2211-3748

Secondary ID2009-012201-19

Secondary IDCTR20130003CFDA

Secondary IDU1111-1113-7090WHO

Timeline

Milestones

Study first posted2010-08-10estimated

Study start2010-08-31actual

Primary completion2015-12-17actual

Study completion2015-12-17actual

Results first posted2017-03-01actual

Last update posted2019-07-17actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Cardiovascular diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

•Type 2 diabetes - Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age min. 60 years at screening and other specified risk factors of cardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s) Exclusion Criteria: - Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness is allowed, at Investigator's discretion

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes

Renal / kidney

Other clinical outcomes

Cardiovascular outcomes

8 endpoints

Primary/registry result

Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

3-point MACE

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke

Posted result

Group	Value (number), percentage of subjects	95% CI
Liraglutide	13.0	—
Placebo	14.9	—

Hazard Ratio (HR)0.86895% CI0.778 – 0.968p<0.001Regression, Cox

Hazard Ratio (HR)0.86895% CI0.778 – 0.968p0.005Regression, Cox

Primary/protocol endpoint

Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

3-point MACE

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke

Secondary/registry result

Time From Rand. to First Occurrence of an Expanded Composite Cardiovascular Outcome Defined as Either Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, Revascularisation, Hospitalisation for Unstable Angina or for Heart Failure.

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Expanded / custom MACE composite

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke, Coronary revascularization, Unstable angina hospitalization, Heart-failure hospitalization

Posted result

Group	Value (number), percentage of subjects	95% CI
Liraglutide	20.3	—
Placebo	22.7	—

Hazard Ratio (HR)0.88195% CI0.807 – 0.962Regression, Cox

Secondary/registry result

Time From Randomisation to All Cause Death

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

All-cause death

time to event, event

SNOMED 419620001

Posted result

Group	Value (number), percentage of subjects	95% CI
Liraglutide	8.2	—
Placebo	9.6	—

Hazard Ratio (HR)0.84795% CI0.739 – 0.971Regression, Cox

Secondary/registry result

Time From Randomisation to Each Individual Component of the Expanded Composite Cardiovascular Outcome

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Expanded / custom MACE composite

time to event, event

Posted result

Group	Value (number), percentage of subjects	95% CI
LiraglutideCardiovascular death	4.7	—
Non-fatal stroke	3.4	—
Non-fatal myocardial infarction	6.0	—
Unstable angina pectoris (hospitalisation)	2.6	—
Coronary revascularisation	8.7	—
Heart failure (hospitalisation)	4.7	—
PlaceboCardiovascular death	6.0	—
Non-fatal stroke	3.8	—
Non-fatal myocardial infarction	6.8	—
Unstable angina pectoris (hospitalisation)	2.7	—
Coronary revascularisation	9.4	—
Heart failure (hospitalisation)	5.3	—

Hazard Ratio (HR)0.78395% CI0.656 – 0.934Regression, Cox

Analysis for percentage of subjects experiencing cardiovascular death was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)0.89495% CI0.721 – 1.107Regression, Cox

Analysis for percentage of subjects experiencing non-fatal stroke was done by Cox regression model with treatment as fixed factor

Hazard Ratio (HR)0.87895% CI0.747 – 1.031Regression, Cox

Analysis for percentage of subjects experiencing non-fatal myocardial infarction was done by Cox regression model with treatment as fixed factor

Hazard Ratio (HR)0.98095% CI0.763 – 1.258Regression, Cox

Analysis for percentage of subjects experiencing hospitalisation for unstable angina pectoris was done by Cox regression model with treatment as fixed factor

Hazard Ratio (HR)0.91295% CI0.797 – 1.044Regression, Cox

Analysis for percentage of subjects experiencing coronary revascularisation was done by Cox regression model with treatment as fixed factor

Hazard Ratio (HR)0.87295% CI0.727 – 1.046Regression, Cox

Analysis for percentage of subjects experiencing hospitalisation for heart failure was done by Cox regression model with treatment as fixed factor

Secondary/protocol endpoint

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Expanded / custom MACE composite

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke, Coronary revascularization, Unstable angina hospitalization, Heart-failure hospitalization

Secondary/protocol endpoint

Time From Randomisation to All Cause Death

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

All-cause death

time to event, event

SNOMED 419620001

Secondary/protocol endpoint/low confidence

Time From Randomisation to Each Individual Component of the Expanded Composite Cardiovascular Outcome

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

time to event, event

Renal / kidney

2 endpoints

Secondary/registry result/low confidence

Time From Randomisation to First Occurrence of a Composite Microvascular Outcome

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Custom renal composite

time to event, event

componentsuACR, change, eGFR, change, Kidney-replacement therapy, Renal death, other clinical outcomes retinopathy procedure or event

Posted result

Group	Value (number), Percentage of subjects	95% CI
Liraglutide	7.6	—
Placebo	8.9	—

Hazard Ratio (HR)0.84195% CI0.730 – 0.969Regression, Cox

Analysis for percentage of subjects experiencing a first microvascular event was done by Cox regression model with treatment as fixed factor.

Secondary/registry result/low confidence

Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

time to event, event

Posted result

Group	Value (number), Percentage of subjects	95% CI
LiraglutideNephropathy composite	5.7	—
New onset of persistent macroalbuminuria	3.4	—
Persistent doubling of serum creatinine	1.9	—
Need for continuous renal-replacement therapy	1.2	—
Death due to renal disease	0.2	—
Retinopathy composite	2.3	—
Treatment with photocoagulation/intravitreal agent	2.1	—
Development of diabetes-related blindness	0.0	—
Vitreous haemorrhage	0.7	—
PlaceboNephropathy composite	7.2	—
New onset of persistent macroalbuminuria	4.6	—
Persistent doubling of serum creatinine	2.1	—
Need for continuous renal-replacement therapy	1.4	—
Death due to renal disease	0.1	—
Retinopathy composite	2.0	—
Treatment with photocoagulation/intravitreal agent	1.8	—
Development of diabetes-related blindness	0.02	—
Vitreous haemorrhage	0.5	—

Hazard Ratio (HR)0.78295% CI0.666 – 0.918Regression, Cox

Analysis for percentage of subjects experiencing a composite nephropathy event was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)0.73895% CI0.602 – 0.905Regression, Cox

Analysis for percentage of subjects experiencing a new onset of persistant macroalbuminaria event was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)0.89095% CI0.667 – 1.189Regression, Cox

Analysis for percentage of subjects experiencing persistent doubling of serum creatinine was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)0.86995% CI0.607 – 1.244Regression, Cox

Analysis for percentage of subjects experiencing a need for continuous renal-replacement therapy was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)1.59395% CI0.521 – 4.869Regression, Cox

Analysis for percentage of subjects experiencing death due to renal disease was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)1.14995% CI0.869 – 1.519Regression, Cox

Analysis for percentage of subjects experiencing composite retinopathy was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)1.15995% CI0.869 – 1.546Regression, Cox

Analysis for percentage of subjects experiencing treatment with photocoagulation or intravitreal agents was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)0.33595% CI0.004 – 30.847Regression, Cox

Analysis for percentage of subjects experiencing development of diabetes-related blindness was done by Cox regression model with treatment as fixed factor.

Hazard Ratio (HR)1.45495% CI0.845 – 2.502Regression, Cox

Analysis for percentage of subjects experiencing vitreous haemorrhage was done by Cox regression model with treatment as fixed factor.

Other clinical outcomes

2 endpoints

Secondary/protocol endpoint/low confidence

Time From Randomisation to First Occurrence of a Composite Microvascular Outcome

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

time to event, event

componentsuACR, change, Custom renal composite, Kidney-replacement therapy, Renal death, other clinical outcomes retinopathy procedure, other clinical outcomes vitreous hemorrhage, other clinical outcomes diabetes related blindness

Secondary/protocol endpoint/low confidence

Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.

Time frame:from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

time to event, event

Publications (42)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
The Cochrane database of systematic reviews2025 Feb 18PMID39963952doi:10.1002/14651858.CD015849.pub2via clinicaltrials gov reference derived + pubmed nct search
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Diabetes, obesity & metabolism2022 Jul (month)PMID35332654doi:10.1111/dom.14700via clinicaltrials gov reference derived + pubmed nct search
A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.
Diabetologia2022 Jan (month)PMID34704120doi:10.1007/s00125-021-05556-7via clinicaltrials gov reference derived + pubmed nct search
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.
Diabetes care2021 Apr (month)PMID33504496doi:10.2337/dc20-1622via clinicaltrials gov reference derived + pubmed nct search
Evaluation of Consistency of Treatment Response Across Regions-the LEADER Trial in Relation to the ICH E17 Guideline.
Frontiers in medicine2021 (year)PMID34136501doi:10.3389/fmed.2021.662775via pubmed nct search
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
Diabetes, obesity & metabolism2020 Dec (month)PMID32744418doi:10.1111/dom.14160via clinicaltrials gov reference derived + pubmed nct search
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
Diabetes, obesity & metabolism2020 Nov (month)PMID32643857doi:10.1111/dom.14140via clinicaltrials gov reference derived + pubmed nct search
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Diabetes, obesity & metabolism2020 Sep (month)PMID32372454doi:10.1111/dom.14079via clinicaltrials gov reference derived + pubmed nct search
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
Diabetes care2020 Sep (month)PMID32647053doi:10.2337/dc20-0437via clinicaltrials gov reference derived + pubmed nct search
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
Diabetes care2020 Jul (month)PMID32366578doi:10.2337/dc19-2251via clinicaltrials gov reference derived + pubmed nct search
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Clinical journal of the American Society of Nephrology : CJASN2020 Apr 7PMID32132141doi:10.2215/CJN.11881019via clinicaltrials gov reference derived + pubmed nct search
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
Journal of the American College of Cardiology2020 Mar 17PMID32164886doi:10.1016/j.jacc.2019.12.063via clinicaltrials gov reference derived + pubmed nct search
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
Diabetes care2020 Feb (month)PMID31959650doi:10.2337/dci19-0067via clinicaltrials gov reference derived + pubmed nct search
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
JAMA cardiology2019 Dec 1PMID31721979doi:10.1001/jamacardio.2019.3080via clinicaltrials gov reference derived + pubmed nct search
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Diabetes, obesity & metabolism2019 Nov (month)PMID31282028doi:10.1111/dom.13826via clinicaltrials gov reference derived + pubmed nct search
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
Diabetes care2019 Oct (month)PMID31399438doi:10.2337/dc19-0415via clinicaltrials gov reference derived + pubmed nct search
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
Diabetes, obesity & metabolism2019 Jul (month)PMID30851070doi:10.1111/dom.13698via CT.gov background + pubmed nct search
Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network.
Diabetes, obesity & metabolism2019 Jul (month)PMID30900349doi:10.1111/dom.13710via CT.gov background
Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.
Annals of internal medicine2019 Mar 19PMID30508430doi:10.7326/M18-1569via CT.gov reference
Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.
Diabetes, obesity & metabolism2019 Mar (month)PMID30260088doi:10.1111/dom.13547via CT.gov reference
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Circulation2018 Dec 18PMID30566006doi:10.1161/CIRCULATIONAHA.118.036418via CT.gov reference + pubmed nct search
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
Circulation2018 Dec 18PMID30566004doi:10.1161/CIRCULATIONAHA.118.034516via CT.gov reference + pubmed nct search
Liraglutide and Glycaemic Outcomes in the LEADER Trial.
Diabetes therapy : research, treatment and education of diabetes and related disorders2018 Dec (month)PMID30392095doi:10.1007/s13300-018-0524-zvia CT.gov reference + pubmed nct search
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
Circulation2018 Oct 9PMID30354517doi:10.1161/CIRCULATIONAHA.118.036862via CT.gov reference
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.
Diabetes care2018 Oct (month)PMID30072400doi:10.2337/dc18-1094via CT.gov reference + pubmed nct search
Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.
Diabetes & vascular disease research2018 Sep (month)PMID29947247doi:10.1177/1479164118783935via CT.gov reference + pubmed nct search
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.
Diabetes care2018 Aug (month)PMID29898902doi:10.2337/dc17-1825via CT.gov reference + pubmed nct search
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
Diabetes care2018 Aug (month)PMID29903847doi:10.2337/dc17-2677via CT.gov reference + pubmed nct search
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).
The American journal of cardiology2018 Jun 15PMID29627109doi:10.1016/j.amjcard.2018.02.030via CT.gov reference + pubmed nct search
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
Circulation2018 May 15PMID29760228doi:10.1161/CIRCULATIONAHA.118.033898via CT.gov reference + pubmed nct search
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
The American journal of managed care2018 Apr (month)PMID29693361via clinicaltrials gov reference derived + pubmed nct search
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.
Diabetes care2018 Mar (month)PMID29279300doi:10.2337/dc17-1956via CT.gov reference + pubmed nct search
Liraglutide and Renal Outcomes in Type 2 Diabetes.
The New England journal of medicine2017 Aug 31PMID28854085doi:10.1056/NEJMoa1616011via CT.gov reference + pubmed nct search
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
Diabetes care2017 Jul (month)PMID28476871doi:10.2337/dc16-2747via CT.gov reference + pubmed nct search
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
The New England journal of medicine2016 Jul 28PMID27295427doi:10.1056/NEJMoa1603827via CT.gov reference + pubmed nct search
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
Journal of hypertension2016 Jun (month)PMID26855018doi:10.1097/HJH.0000000000000890via CT.gov reference + pubmed nct search
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.
Cardiovascular diabetology2016 Feb 10PMID26864124doi:10.1186/s12933-016-0341-5via CT.gov reference + pubmed nct search
LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population.
Journal of diabetes and its complications2016 Nov-Dec (year)PMID27320184doi:10.1016/j.jdiacomp.2016.06.001via CT.gov reference + pubmed nct search
LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.
Diabetology & metabolic syndrome2016 (year)PMID27274772doi:10.1186/s13098-016-0153-5via CT.gov reference + pubmed nct search
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.
Diabetes, obesity & metabolism2015 May (month)PMID25656058doi:10.1111/dom.12444via CT.gov reference
LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
Pancreas2014 Nov (month)PMID25275271doi:10.1097/MPA.0000000000000229via CT.gov reference + pubmed nct search
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
American heart journal2013 Nov (month)PMID24176437doi:10.1016/j.ahj.2013.07.012via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.